WHO Guideline on Country Pharmaceutical Pricing Policies, published in 2020, outlines 10 commonly used pricing methods internationally. However, due to the unique composition of costs for traditional Chinese medicine (TCM), directly applying pricing methods designed for chemical and biological drugs may lead to discrepancies. Currently, in China, drug pricing primarily in- volves internal reference pricing, tender negotiation pricing, promoting the use of quality-assured generic and biosimilar drugs, and centralized procurement. It systematically analyzes various pricing methods and identifies their applicability and underlying reasons concerning the pricing of TCM within the medical insurance system. The method of value-based pricing and increasing price transparency has advantages for the pricing regulation of traditional Chinese medicine under medical insurance.